Just - Evotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related Viruses

Core Insights - Just - Evotec Biologics has entered a project agreement with BARDA to optimize biomanufacturing of antibodies against Ebola and related viruses, enhancing U.S. government response capabilities to hemorrhagic fever outbreaks [1][2] Group 1: Project Agreement Details - The multi-year program is valued at up to $10 million if all options are activated, aimed at developing cost-effective medical countermeasures for filovirus diseases [2] - The agreement includes a base period and two option periods, addressing the lack of approved treatments for Sudan virus infections [2] Group 2: Technological Approach - Just - Evotec Biologics will utilize its advanced biomanufacturing platform for molecular optimization, cell line development, and manufacturing process development for two antibodies identified in Ebola survivors [3] - The focus is on delivering high-yield, scalable, and cost-efficient production processes to support rapid deployment in public health emergencies [3] Group 3: Organizational Background - Just - Evotec Biologics is a subsidiary of Evotec SE, leveraging AI/ML technologies and advanced manufacturing strategies to accelerate biotherapeutics from discovery to commercial launch [7] - Evotec SE is a life science company that integrates breakthrough science with AI-driven innovation, focusing on drug discovery and development across various therapeutic areas [8]